Company Description
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Guo-Liang Yu |
Contact Details
Address: 989 East Hillsdale Blvd., Suite 220 Foster City, California 94404 United States | |
| Phone | 650 209 4055 |
| Website | apollomicsinc.com |
Stock Details
| Ticker Symbol | APLM |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001944885 |
| ISIN Number | KYG0411D1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Guo-Liang Yu Ph.D. | Co-Founder, Chief Executive Officer and Executive Chairman |
| Dr. Sanjeev Redkar MBA, Ph.D. | Co-Founder and Executive Director |
| Dr. Matthew James Plunkett Ph.D. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 3, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 6-K | Report of foreign issuer |
| Jan 10, 2025 | SCHEDULE 13G/A | Filing |
| Dec 20, 2024 | 6-K | Report of foreign issuer |
| Dec 10, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Aug 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 14, 2024 | 6-K | Report of foreign issuer |